Pharmaceutical Savings After Roux-en-Y Gastric Bypass Obesity Surgery
Medication Cost Savings After Roux-en-Y Stomach Bypass Surgery
| Bariatric Surgery information Pharmaceutical Savings After Roux-en-Y Gastric Bypass Obesity Surgery |
Medication Cost Savings After Roux-en-Y Stomach Bypass Surgery |
|
Weight Loss Surgery Information - Bariatric Research Studies |
Pharmaceutical Savings After Roux-en-Y Gastric Bypass Obesity SurgeryClinically severe obesity (CSO) is a surgically treated disease.The Roux-en-Y gastric bypass (RYGBP) has been used to treat patients with CSO and has resulted in an improvement in co-morbidities. We speculated that after a period of weight loss, patients would require less medication, resulting in cost-savings to both the patient and the insurance company, as well as an overall gain in health. Method A retrospective study was performed which involved the first 100 patients who had undergone Roux-en-Y gastric bypass at a community-teaching hospital. Analysis of the data was conducted by the Wilcoxon signed rank test. Results 64 patients met our inclusion criteria and had adequate follow-up data available. The mean BMI was 57 kg/m(2), the female to male ratio was 4:1, and the mean age was 44 years. The average monthly medication expenditure was reduced from US dollars 317 preoperatively, to US dollars 135 postoperatively. This reduction is significant. Conclusion Weight loss after Roux-en-Y gastric bypass leads to a significant reduction in medication expenses. These medication savings offset the costs of the initial procedure and represent permanent financial savings for the patient and society. Authors: Gastric Bypass Weight Loss Surgery |